Recent clinical data confirms significantly improved predictive power of evaxion's ai-immunology™ platform

Copenhagen, denmark, october 3, 2024 – evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, continues to gather clinical evidence for the steady improvement of its ai-immunology™ platform.

EVAX Ratings Summary

EVAX Quant Ranking